<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38727085</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>05</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>5</Issue><PubDate><Year>2024</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Clinical effectiveness of nirmatrelvir plus ritonavir on the short- and long-term outcome in high-risk children with COVID-19.</ArticleTitle><Pagination><StartPage>e29662</StartPage><MedlinePgn>e29662</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.29662</ELocationID><Abstract><AbstractText>This study investigated the clinical effectiveness of nirmatrelvir plus ritonavir (NMV-r) on short-term outcome and the risk of postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) among pediatric patients with coronavirus disease 2019 (COVID-19). This retrospective cohort study used the TriNetX research network to identify pediatric patients between 12 and 18 years with COVID-19 between January 1, 2022 and August 31, 2023. The propensity score matching (PSM) method was used to match patients receiving NMV-r (NMV-r group) with those who did not receive NMV-r (control group). Two cohorts comprising 633 patients each (NMV-r and control groups), with balanced baseline characteristics, were identified using the PSM method. During the initial 30 days, the NMV-r group showed a lower incidence of all-cause hospitalization, mortality, or ED visits (hazard ratio [HR]&#x2009;=&#x2009;0.546, 95% confidence interval [CI]: 0.372-0.799, p&#x2009;=&#x2009;0.002). Additionally, the NMV-r group had a significantly lower risk of all-cause hospitalization compared with the control group (HR&#x2009;=&#x2009;0.463, 95% CI: 0.269-0.798), with no deaths occurring in either group. In the 30-180-day follow-up period, the NMV-r group exhibited a non-significantly lower incidence of post-acute sequelae of SARS-CoV-2 infection (PASC), encompassing symptoms such as fatigue, cardiopulmonary symptoms, pain, cognitive impairments, headache, dizziness, sleep disorders, anxiety, and depression, compared to the control group. This study underscores the potential effectiveness of NMV-r in treating high-risk pediatric patients with COVID-19, demonstrating significant reductions in short-term adverse outcomes such as emergency department visits, hospitalization, or mortality within the initial 30-day period. Additionally, NMV-r shows promise in potentially preventing the development of PASC.</AbstractText><CopyrightInformation>&#xa9; 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jheng-Yan</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-3290-1909</Identifier><AffiliationInfo><Affiliation>Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Chia-Chen</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Chi Mei Medical Center, Liouying, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mei-Yuan</ForeName><Initials>MY</Initials><AffiliationInfo><Affiliation>Department of Nutrition, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nutrition and Health Sciences, Chang Jung Christian University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Food Nutrition, Chung Hwa University of Medical Technology, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health and Nutrition, Chia Nan University of Pharmacy &amp; Science, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hsu</LastName><ForeName>Wan-Hsuan</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Ya-Wen</ForeName><Initials>YW</Initials><Identifier Source="ORCID">0000-0003-4630-3923</Identifier><AffiliationInfo><Affiliation>Center of Integrative Medicine, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Ting-Hui</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pin-Chien</LastName><ForeName>Sung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Po-Yu</ForeName><Initials>PY</Initials><Identifier Source="ORCID">0000-0002-8682-1322</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Min-Hsiang</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Division of Nephrology, Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Mei-Chuan</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacy, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Kuo-Chuan</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0002-4507-8085</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Tsung</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Chih-Cheng</ForeName><Initials>CC</Initials><Identifier Source="ORCID">0000-0002-6334-2388</Identifier><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="Y">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2 infection</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">nirmatrelvir plus ritonavir</Keyword><Keyword MajorTopicYN="N">pediatric</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>10</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>5</Month><Day>10</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>5</Month><Day>10</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38727085</ArticleId><ArticleId IdType="doi">10.1002/jmv.29662</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS&#x2010;CoV&#x2010;2) and coronavirus disease&#x2010;2019 (COVID&#x2010;19): the epidemic and the challenges. Int J Antimicro Ag. 2020;55(3):105924.</Citation></Reference><Reference><Citation>World Health Organization. Accessed on March 18, 2024. https://data.who.int/dashboards/covid19/cases</Citation></Reference><Reference><Citation>Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS&#x2010;CoV&#x2010;2): facts and myths. J Microbiol Immunol Infect. 2020;53(3):404&#x2010;412.</Citation></Reference><Reference><Citation>Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 (COVID&#x2010;19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicro Ag. 2020;55(4):105946.</Citation></Reference><Reference><Citation>Azzam A, Khaled H, Refaey N, et al. The burden of persistent symptoms after COVID&#x2010;19 (long COVID): a meta&#x2010;analysis of controlled studies in children and adults. Virol J. 2024;21(1):16.</Citation></Reference><Reference><Citation>Kulkarni D, Ismail NF, Zhu F, et al. Epidemiology and clinical features of SARS&#x2010;CoV&#x2010;2 infection in children and adolescents in the pre&#x2010;omicron era: a global systematic review and meta&#x2010;analysis. J Glob Health. 2024;14:05003.</Citation></Reference><Reference><Citation>Tan MS, Zulkifli NA, Teng W, Lim PT. Clinical outcomes of children with COVID&#x2010;19 infection in a low&#x2010;risk centre in Malaysia. Med J Malaysia. 2023;78(7):853&#x2010;856.</Citation></Reference><Reference><Citation>Chang YJ, Huang CG, Shie SS, Lin JJ, Chen CJ. Clinical features and virologic lineages of COVID&#x2010;19&#x2010;associated encephalitis in Taiwanese children during early epidemic wave of omicron in 2022: report from a medical center. J Microbiol Immunol Infect. 2024;57(1):48&#x2010;54.</Citation></Reference><Reference><Citation>Huang CW, Lin JJ, Kuo CY, et al. Risk factors of Omicron variant associated acute encephalitis/encephalopathy in children. J Microbiol Immunol Infect. 2023;56(6):1169&#x2010;1177.</Citation></Reference><Reference><Citation>Huang SM, Wu CH, Yen TY, et al. Clinical characteristics and factors associated with severe COVID&#x2010;19 in hospitalized children during the SARS&#x2010;CoV&#x2010;2 Omicron pandemic in Taiwan. J Microbiol Immunol Infect. 2023;56(5):961&#x2010;969.</Citation></Reference><Reference><Citation>Badal S, Thapa Bajgain K, Badal S, Thapa R, Bajgain BB, Santana MJ. Prevalence, clinical characteristics, and outcomes of pediatric COVID&#x2010;19: A systematic review and meta&#x2010;analysis. J Clin Virol. 2021;135:104715.</Citation></Reference><Reference><Citation>Patel NA. Pediatric COVID&#x2010;19: systematic review of the literature. Am J Otolaryngol. 2020;41(5):102573.</Citation></Reference><Reference><Citation>Younger DS. Post&#x2010;acute sequelae of SARS&#x2010;CoV&#x2010;2 infection (PASC): peripheral, autonomic, and central nervous system features in a child. Neurol Sci. 2021;42:3959&#x2010;3963.</Citation></Reference><Reference><Citation>Rao S, Lee GM, Razzaghi H, et al. Clinical features and burden of postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection in children and adolescents. JAMA Pediatr. 2022;176(10):1000&#x2010;1009.</Citation></Reference><Reference><Citation>Groff D, Sun A, Ssentongo AE, et al. Short&#x2010;term and long&#x2010;term rates of postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection: a systematic review. JAMA Netwk Open. 2021;4(10):e2128568&#x2010;e.</Citation></Reference><Reference><Citation>Rao S, Lee GM, Razzaghi H, et al. Clinical features and burden of postacute sequelae of SARS&#x2010;CoV&#x2010;2 infection in children and adolescents. JAMA Pediatr. 2022;176(10):1000&#x2010;1009.</Citation></Reference><Reference><Citation>Lai CC, Hsu CK, Yen MY, Lee PI, Ko WC, Hsueh PR. Long COVID: an inevitable sequela of SARS&#x2010;CoV&#x2010;2 infection. J Microbiol Immunol Infect. 2023;56(1):1&#x2010;9.</Citation></Reference><Reference><Citation>Wu J&#x2010;Y, Liu M&#x2010;Y, Liu T&#x2010;H, et al. Association between nirmatrelvir plus ritonavir and the outcomes of non&#x2010;hospitalized obese patients with COVID&#x2010;19. Int J Antimicro Ag. 2023;62(6):106984.</Citation></Reference><Reference><Citation>Liu TH, Wu JY, Huang PY, et al. Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID&#x2010;19 and preexisting cardiovascular diseases. Expert Rev Anti Infect Ther. 2024;22(1&#x2010;3):121&#x2010;128.</Citation></Reference><Reference><Citation>Liu TH, Wu JY, Huang PY, Tsai YW, Lai CC. The effect of nirmatrelvir plus ritonavir on the long&#x2010;term risk of epilepsy and seizure following COVID&#x2010;19: a retrospective cohort study including 91,528 patients. J Infect. 2023;86(3):256&#x2010;308.</Citation></Reference><Reference><Citation>Chuang MH, Wu JY, Liu TH, et al. Efficacy of nirmatrelvir and ritonavir for post&#x2010;acute COVID&#x2010;19 sequelae beyond 3 months of SARS&#x2010;CoV&#x2010;2 infection. J Med Virol. 2023;95(4):e28750.</Citation></Reference><Reference><Citation>Tsai YW, Wu JY, Liu TH, et al. Clinical effectiveness of oral antiviral agents in older patients with COVID&#x2010;19 based on real&#x2010;world data. J Med Virol. 2023;95(6):e28869.</Citation></Reference><Reference><Citation>Wu JY, Liu MY, Liu TH, et al. Association between nirmatrelvir plus ritonavir and the outcomes of non&#x2010;hospitalized obese patients with COVID&#x2010;19. Int J Antimicro Ag. 2023;62(6):106984.</Citation></Reference><Reference><Citation>FDA. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid. https://www.fda.gov/media/155050/download</Citation></Reference><Reference><Citation>Esposito S, Autore G, Argentiero A, Ramundo G, Perrone S, Principi N. Update on COVID&#x2010;19 therapy in pediatric age. Pharmaceuticals. 2022;15(12):1512.</Citation></Reference><Reference><Citation>Yang CC, Tsai YW, Wang SH, et al. The effectiveness of oral anti&#x2010;SARS&#x2010;CoV&#x2010;2 agents in non&#x2010;hospitalized COVID&#x2010;19 patients with nonalcoholic fatty liver disease: a retrospective study. Front Pharmacol. 2024;15:1321155.</Citation></Reference><Reference><Citation>Wu JY, Liu MY, Liu TH, et al. Clinical efficacy of nirmatrelvir and ritonavir combination for treating diabetic patients with COVID&#x2010;19. J Med Virol. 2023;95(6):e28866.</Citation></Reference><Reference><Citation>Wu JY, Liu MY, Lee MC, et al. The clinical outcomes and effectiveness of antiviral agents among underweight patients with COVID&#x2010;19. Expert Rev Anti Infect Ther. 2024;4:1&#x2010;10.</Citation></Reference><Reference><Citation>Wu J&#x2010;Y, Hsu W&#x2010;H, Tsai Y&#x2010;W, et al. The association between zinc deficiency, and clinical outcomes of COVID&#x2010;19. J Infect. 2023;87(4):e63&#x2010;e67.</Citation></Reference><Reference><Citation>Hsu W&#x2010;H, Tsai Y&#x2010;W, Wu J&#x2010;Y, Liu T&#x2010;H, Lai C&#x2010;C. Post&#x2010;acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID&#x2010;19 survivors. J Infect. 2023;86(4):e107&#x2010;e110.</Citation></Reference><Reference><Citation>Tsai Y&#x2010;W, Tsai C&#x2010;F, Wu J&#x2010;Y, Huang P&#x2010;Y, Liu T&#x2010;H, Lai C&#x2010;C. The risk of methicillin&#x2010;resistant Staphylococcus aureus infection following COVID&#x2010;19 and influenza: a retrospective cohort study from the TriNetX network. J Infect. 2023;86(3):256&#x2010;308.</Citation></Reference><Reference><Citation>Gao Y, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID&#x2010;19 patients: A review. Allergy. 2021;76(2):428&#x2010;455.</Citation></Reference><Reference><Citation>Siemieniuk RA, Bartoszko BJ, Zeraatkar D, et al. Drug treatments for covid&#x2010;19: living systematic review and network meta&#x2010;analysis. BMJ. 2020;370:m2980.</Citation></Reference><Reference><Citation>Hsu WH, Shiau BW, Liu TH, et al. Clinical effectiveness of nirmatrelvir plus ritonavir in the treatment of COVID&#x2010;19 in patients with cirrhosis. Expert Rev Anti Infect Ther. 2023;21(10):1143&#x2010;1151.</Citation></Reference><Reference><Citation>Congdon S, Narrowe Z, Yone N, et al. Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study. Sci Rep. 2023;13(1):19688.</Citation></Reference><Reference><Citation>Sherif ZA, Gomez CR, Connors TJ, Henrich TJ, Reeves WB. Pathogenic mechanisms of post&#x2010;acute sequelae of SARS&#x2010;CoV&#x2010;2 infection (PASC). eLife. 2023;12:e86002.</Citation></Reference><Reference><Citation>Bose&#x2010;Brill S, Hirabayashi K, Pajor NM, et al. Pediatric nirmatrelvir/ritonavir prescribing patterns during the COVID&#x2010;19 pandemic. medRxiv. Preprint published online December 26, 2022.</Citation></Reference><Reference><Citation>Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of America Guidelines on the treatment and management of patients with COVID&#x2010;19. Clin Infect Dis. 2022;27:ciaa478.</Citation></Reference><Reference><Citation>Gupta S. Intention&#x2010;to&#x2010;treat concept: a review. Perspect Clin Res. 2011;2(3):109&#x2010;112.</Citation></Reference><Reference><Citation>Copeland KT, Checkoway H, McMichael AJ, Holbrook RH. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol. 1977;105(5):488&#x2010;495.</Citation></Reference><Reference><Citation>Serdar CC, Cihan M, Y&#xfc;cel D, Serdar MA. Sample size, power and effect size revisited: simplified and practical approaches in pre&#x2010;clinical, clinical and laboratory studies. Biochem Med. 2021;31(1):010502.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>